Wang C C, Montgomery W, Efird J
Department of Radiation Oncology, Massachusetts General Hospital, Boston 02114, USA.
Laryngoscope. 1995 May;105(5 Pt 1):529-33. doi: 10.1288/00005537-199505000-00016.
The authors of this study reviewed the management of 402 patients with squamous cell carcinomas of the faucial tonsil and the base of the tongue. These patients received radiation therapy at Massachusetts General Hospital and the Massachusetts Eye and Ear Infirmary from 1970 through 1993. Radiation therapy remains the treatment of choice for these lesions. Although the data from this review were not randomized, the accelerated hyperfractionated radiation therapy twice-daily program was shown to achieve significantly higher 5-year local tumor control rates and disease-specific survival rates than the conventional once-daily radiation therapy program (historical control). In patients with early tumors of the faucial tonsil (cancer stages T1 and T2), the 5-year actuarial local tumor control and disease-specific survival rates following the twice-daily radiation therapy program were 91% and 77%, respectively. In patients with advanced tumors (T3), the corresponding rates following twice-daily radiation therapy showed marked improvement and were 80% and 68%. While the treatment results for carcinoma of the base of the tongue generally were inferior to those for carcinoma of the faucial tonsil, they were still much better after the twice-daily program than after conventional once-daily irradiation. For patients with carcinoma of the base of the tongue, the local tumor control and disease-specific survival rates for T1 and T2 lesions were 85% and 76%, respectively. For T3 lesions, the corresponding rates were 54% and 53%. Extensive T4 tumors are better managed by combined surgery and postoperative irradiation. Residual metastatic nodal disease is managed by neck dissection.
本研究的作者回顾了402例扁桃体和舌根鳞状细胞癌患者的治疗情况。这些患者于1970年至1993年在马萨诸塞州总医院和马萨诸塞州眼耳医院接受了放射治疗。放射治疗仍然是这些病变的首选治疗方法。尽管本综述的数据并非随机分组,但与传统的每日一次放射治疗方案(历史对照)相比,每日两次的加速超分割放射治疗方案显示出5年局部肿瘤控制率和疾病特异性生存率显著更高。在扁桃体早期肿瘤(癌症分期为T1和T2)患者中,每日两次放射治疗方案后的5年精算局部肿瘤控制率和疾病特异性生存率分别为91%和77%。在晚期肿瘤(T3)患者中,每日两次放射治疗后的相应比率有显著改善,分别为80%和68%。虽然舌根癌的治疗结果总体上不如扁桃体癌,但每日两次方案后的结果仍比传统的每日一次照射要好得多。对于舌根癌患者,T1和T2病变的局部肿瘤控制率和疾病特异性生存率分别为85%和76%。对于T3病变,相应的比率分别为54%和53%。广泛的T4肿瘤通过手术联合术后放疗进行更好的治疗。残留的转移性淋巴结疾病通过颈部清扫进行治疗。